Meeting
2020 ASCO Virtual Scientific Program
EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.
Presenter
Justine Yang Bruce, MD
Carbone Cancer Center, University of Wisconsin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Immunoconjugates (non-IO)
Clinical Trial Registration Number
NCT04225117
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3647)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3647
Abstract #
TPS3647
Poster Bd #
377
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.
Speaker: Sonia Pernas, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4.
Speaker: Meredith Pelster, MD, MSc
Speaker: Panel Discussion
Videos & Slides
2023 ASCO Annual Meeting
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
Speaker: Li Zhang, MD